|
Market Closed -
London S.E.
16:35:14 03/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 0.1000 GBX | -6.54% |
|
-4.76% | -60.78% |
| 10-22 | WINNERS & LOSERS: Camellia slumps on macadamia woe; Record climbs | AN |
| 10-20 | WINNERS & LOSERS: Ixico beats expectations; Shearwater wins deal | AN |
| Market Cap | 3.78M 5.08M 4.54M 4.17M 7.11M 481M 7.28M 49.74M 20.01M 254M 19.06M 18.65M 805M | P/E 2024 |
-0.13x | P/E 2025 | -5.88x |
|---|---|---|---|---|---|
| Enterprise Value | 3.69M 4.95M 4.42M 4.06M 6.92M 469M 7.1M 48.45M 19.49M 247M 18.57M 18.17M 784M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
94.63% | Yield 2024 * |
-
| Yield 2025 | - |
London S.E.GBX
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| LVRT | Delayed | |
Deutsche Boerse AG
| 1RT | Delayed | |
|
Börse Stuttgart
| 1RT | Delayed |
| 23/05/25 | Nuformix : Prospectus | PU |
| 05/10/23 | Nuformix to fund its unlicensed programs with NXP001 windfall | AQ |
| 20/12/22 | Nuformix hoping to "initiate discussions with major pharma" in 2023 | AQ |
| 20/12/22 | Nuformix hoping to 'initiate discussions with major pharma' in 2023 | EQ |
| 18/02/20 | Nuformix : Appointment of Dr Karl Keegan | PU |
| 1 day | -6.54% | ||
| 1 week | -4.76% | ||
| Current month | -4.76% | ||
| 1 month | -25.93% | ||
| 3 months | -33.99% | ||
| 6 months | -39.39% | ||
| Current year | -60.78% |
| 1 week | 0.09 |  | 0.11 |
| 1 month | 0.09 | | 0.14 |
| Current year | 0.09 | | 0.4 |
| 1 year | 0.09 | | 0.56 |
| 3 years | 0.04 | | 0.56 |
| 5 years | 0.04 | | 1.93 |
| 10 years | 0.04 | | 14.89 |
| Manager | Title | Age | Since |
|---|---|---|---|
Shaun Zulafqar
SEC | Corporate Secretary | - | 28/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Daniel Gooding
BRD | Director/Board Member | 53 | 30/06/2022 |
| Director/Board Member | 61 | 01/12/2020 | |
Timothy Metcalfe
CHM | Chairman | 54 | 31/08/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 05/11/24 | Free | Director | 22,000,000 | 2.6852% | ||
| 05/11/24 | Free | Chairman | 22,000,000 | 2.6852% | ||
| 05/11/24 | Free | Founder | 12,000,000 | 1.4646% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.54% | -4.76% | -79.38% | -63.64% | 3.75M | |
| +0.69% | +10.69% | +58.26% | +149.89% | 1,257B | |
| -1.21% | -0.34% | +43.78% | +76.96% | 651B | |
| 0.00% | +0.74% | +36.11% | +104.01% | 510B | |
| -1.56% | -2.01% | +50.67% | +64.81% | 388B | |
| -2.36% | +2.02% | +75.40% | +39.95% | 366B | |
| -0.02% | +2.11% | +32.16% | +57.79% | 303B | |
| -0.72% | +7.32% | +11.29% | +33.98% | 288B | |
| -0.45% | +3.50% | +56.47% | +71.80% | 252B | |
| -0.80% | +6.36% | +38.62% | +107.37% | 211B | |
| Average | -1.25% | +4.84% | +32.34% | +64.29% | 422.67B | |
| Weighted average by Cap. | -0.42% | +5.30% | +47.98% | +94.50% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -3.64M -4.89M -4.37M -4.01M -6.84M -463M -7.01M -47.86M -19.25M -244M -18.34M -17.95M -774M | -653K -876K -782K -719K -1.23M -82.94M -1.26M -8.58M -3.45M -43.78M -3.29M -3.22M -139M |
| Net Debt | -20.21K -27.12K -24.23K -22.25K -37.95K -2.57M -38.91K -266K -107K -1.36M -102K -99.6K -4.3M | -97.55K -131K -117K -107K -183K -12.4M -188K -1.28M -516K -6.54M -491K -481K -20.74M |
Employees
3
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/11/26 | GBX 0.1000 | -6.54% | 32,899,955 |
| 02/11/26 | GBX 0.1070 | +1.90% | 2,935,171 |
| 30/10/26 | GBX 0.1050 | 0.00% | 3,668,015 |
| 29/10/26 | GBX 0.1050 | 0.00% | 7,780,430 |
| 28/10/26 | GBX 0.1050 | 0.00% | 7,162,872 |
- Stock Market
- Stocks
- LVRT Stock
Select your edition
All financial news and data tailored to specific country editions
